WO2011144059A1 - 一种稠环喹唑啉类衍生物及其应用 - Google Patents
一种稠环喹唑啉类衍生物及其应用 Download PDFInfo
- Publication number
- WO2011144059A1 WO2011144059A1 PCT/CN2011/074434 CN2011074434W WO2011144059A1 WO 2011144059 A1 WO2011144059 A1 WO 2011144059A1 CN 2011074434 W CN2011074434 W CN 2011074434W WO 2011144059 A1 WO2011144059 A1 WO 2011144059A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- quinazoline
- group
- quinazolino
- methoxyethoxy
- bis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to a novel class of fused ring quinazoline derivatives. Background technique
- the protein tyrosine kinase family is extensively involved in cell signaling through phosphorylation and dephosphorylation in a transmembrane receptor or cytoplasmic form. During tumorigenesis, a variant or overexpressed protein tyrosine kinase can transform normal cells into cancer cells while promoting tumor cell growth and mitosis. Therefore, agonists or inhibitors of these enzymes can be used for the treatment of tumors.
- Epidermal growth factor receptor (EGFR) tyrosine kinase family including four members: ErbB-1, ErbB-2, ErbB-3. ErbB4.
- VEGFR vascular endothelial growth factor receptor
- Aurora kinase is an important class of serine/threonine kinases in the mitotic regulatory network of cells.
- the Aurora family is divided into Aurora A, Aurora B and Aurora C. They function in the mitotic checkpoint adjustment channel. Abnormal expression of Aurora kinase is likely to interfere with the function of the checkpoint in mitosis, which may lead to genetic instability and tumor growth.
- Aurora kinase is not only closely related to tumors, but also Aurora kinase inhibitors have shown strong anti-tumor ability. They have good inhibitory activity against Aurora A and Aurora B. Some inhibitors have entered preclinical and phase I clinical trials. Including Hesperadin, ZM447439, MK0457 also known as VX-680), AZD1152, MLN8054 PHA-739358 and so on.
- Each R 1 is independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, hydroxyamino, carboxy, (dC 4 ) fluorenyloxy, nitro, decyl, ureido, carbamoyl, cyano, trifluoromethyl, CM alkenyl-W-phenyl-alkyl, wherein W is selected from the group consisting of a single bond, O, S, NH: R 4 is an azide group, a substituted or unsubstituted ethynyl group.
- R 1 is hydrogen or a fluorenyl group which may be optionally substituted by the following groups: halogen, CM alkoxy, -NR 6 R 7 , replacement page (Article 26) -S0 2 5 ; each R 2 may be optionally selected from the group consisting of halogen, hydroxy, d- 6 alkoxy, -NR 6 R 7 , d_ 4 alkoxy, wherein said alkyl group and said R 2
- the intermediate alkyl moiety may be freely substituted by 1 to 3 of the following groups: halogen, C ⁇ alkoxy, -N 6 7 , -S0 2 5 ; R 3 is azide or ethynyl-R 8 , wherein R 8 is hydrogen or d- 6 alkyl which may be optionally substituted by a hydroxyl group, -OR 6 , -NR 6 R 7 ; is hydrogen, d 4 alkyl, (d 4 alkoxy) - d 4 alkyl,
- the technical problem to be solved by the present invention is to disclose a class of fused ring quinazoline derivatives, which are novel protein tyrosine kinase inhibitors and aurora kinase inhibitors to meet the needs of clinical applications.
- the fused ring quinazoline compound of the present invention is a hydrate having the following formula (V): a compound of the formula: or a salt or a salt thereof:
- d_C 4 alkynyl nitro, amino, hydroxy, hydroxymethyl, alkyl sulfonate, d_C 4 alkyl, d_C 4 alkoxy Base, d_C 4 acylamino group, benzoylamino group, d_C 4 substituted amino group, d_C 4 unsaturated fatty chain, 5-membered aliphatic ring, 6-membered aliphatic ring, substituted phenyl group, phenyl group, substituted benzyl Oxyl or heterocyclic;
- R4 is hydrogen, trifluoromethyl, an alkyl group of - or an alkoxy group of d_C 4 ;
- R 2 , R 3 , R 4 and R 5 are not hydrogen at the same time.
- 2 is hydrogen, halogen, amino, nitro, hydroxyamino, carboxy, -C4 alkoxycarbonyl, d_C 4 alkyl, d_C 4 acylamino, (E)-4-(dimethylamino)-2-butyl
- R4 is hydrogen, trifluoromethyl, an alkyl group of - or an alkoxy group of d_C 4 ;
- R 2 , R 3 , R 4 and R 5 are not hydrogen at the same time.
- the salt is a pharmaceutically acceptable salt, preferably a hydrochloride, a hydrobromide, a sulfate, an acetate, a lactate, a tartrate, a citrate, a citrate or a trifluoroacetate.
- malate, maleate, succinate, p-toluenesulfonate or methanesulfonate, etc. the salt does not contain crystal water or crystal water, preferably 0.5-3.0 molecules of crystal water.
- the halogen is preferably fluorine, chlorine, bromine or iodine.
- the amino group means -NH 2
- the substituted amino group means that a hydrogen atom on -NH 2 is partially or completely substituted by an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group or the like, and a substituted amino group of d_C 4 is preferably a methylamino group.
- alkoxy refers to an alkyl ether radical, preferably an alkoxy group of C r C 4 , a benzyloxy or substituted benzyloxy group, a pyrrolidin-1-yl-(C 2 -C 4 ) alkoxy group.
- the alkoxy group of dC 4 is preferably methoxy, ethoxy, n-propyl An oxy group, an isopropoxy group, a n-butoxy group, an isobutoxy group, a methoxyethoxy group, an ethoxymethoxy group or the like;
- the d_C 4 alkoxycarbonyl group is preferably methoxymethylcarbonyl CH 3 OC(0)-, ethoxymethylcarbonyl CH 3 CH 2 OC(0)-, propoxymethylcarbonyl, isopropoxycarbonyl, n-butoxy Carbonyl group and the like.
- the alkyl group means a branched, unbranched and cyclic saturated hydrocarbon chain containing a specified number of carbon atoms
- the alkyl group of dC 4 is preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, Butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, methoxyethyl, methoxy-n-propyl, methoxy isopropyl, ethoxymethyl, ethoxy Ethyl, n-propoxy
- the amide group means a -C (0) NH -
- "amide group is Ci-C 4" is preferably acetylamino (CH 3 C (0) NH -), propionamido (CH 3 CH 2 C (0 ) NH -), butyrylamino or isobutyrylamino and the like.
- the sulfonyl group means -S0 2 - ;
- sulfonyl group of dC 4 means "alkyl group of dC 4 " is bonded to "sulfonyl group", preferably methanesulfonyl group (Ms), ethyl sulfonate Acyl, propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl 115, sec-butylsulfonyl;
- said "aryl” means one, two or three substituted or unsubstituted
- An aromatic ring system in which such rings may be linked together in a suspended manner or may be fused, preferably phenyl, naphthyl, anthracenyl, phenanthryl, and diphenyl, 3-fluorophenyl, 2- Bromophenyl, 3-chloronaph
- substituted phenyl means that some or all of the hydrogen atoms on the benzene ring are independently substituted with a substituent, and preferably the benzene ring contains 1 to 4 substituents, and the substituent may be a halogen, a hydroxyl group or a nitrate. group, a cyano group, an alkoxy group d_c 4, 120 d_C 4 alkyl or an amino group, such as 3-fluorophenyl, 2-bromophenyl group and the like.
- heterocyclic ring means a ring containing one or more hetero atoms in the ring of the aliphatic ring, a hetero atom is nitrogen, oxygen or sulfur, preferably a saturated or unsaturated five-membered or six-membered heterocyclic ring, preferably furan, four Hydropyrrole, dihydropyrazole, piperidine, piperidine, morpholine, imidazole or pyridine, etc., the one or more refers to two, three, or four.
- substituted heterocyclic ring means that the hydrogen atom on the hetero ring may be independently substituted by a substituent, and the "substituted heterocyclic ring” is preferably 5-((2-(methylsulfonyl)ethylamino)methyl)-) Furan.
- the "unsaturated aliphatic chain” refers to a branched, unbranched and cyclic unsaturated hydrocarbon chain containing a specified number of carbon atoms
- the unsaturated fatty chain of dC 4 means a vinyl group, a propenyl group, an isopropenyl group. , butenyl, isobutenyl, sec-butenyl, ethynyl, propynyl or butynyl and the corresponding counterparts, and the like.
- the C 2 -C 4 alkynyl group means an ethynyl group, a propynyl group, a butynyl group or an isobutynyl group.
- the five-membered aliphatic ring means a substituted or unsubstituted five-membered aliphatic ring
- the six-membered aliphatic ring means a substituted or unsubstituted six-membered aliphatic ring.
- the alkyl sulfonate refers to an ester composed of "alkyl alcohol” and "alkyl sulfonic acid", and the alkyl alcohol is preferably a dC 4 alkyl alcohol such as methanol, ethanol, n-propanol, isopropanol, n-butanol, etc.
- the alkylsulfonic acid is preferably an alkylsulfonic acid of dC 4 such as methanesulfonic acid, ethanesulfonic acid 135 or the like, and the alkylsulfonate is preferably methanolic mesylate (-CH 2 OMs).
- the R 3 is hydrogen, halogen, trifluoromethyl, cyano, ethynyl, nitro, amino, hydroxy, hydroxymethyl, methanesulfonate, methoxy, acetamido, benzoylamino, 3-fluorobenzyloxy
- R 2 , R 3 , R 4 and R 5 are not hydrogen at the same time.
- the compounds of the invention may include, but are not limited to, the following preferred compounds:
- V-1 9-Chloro-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline hydrochloride monohydrate
- Vr 9-chloro -2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline Vr 9-chloro -2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline
- V-3 9-fluoro-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline mesylate
- V-3' 9- Fluorin-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline
- V-4 9-ethynyl-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline hydrochloride trihydrate
- V-7 9-cyano-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline
- V-14 9-chloro-10-P-fluorobenzyloxy)-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline
- V-15 11-chloro-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline
- V-21 9-Amino-11-hydroxymethyl-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline
- V-22 11 -Chloro-8-methyl-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline malate
- V-22' 11- Chloro-8-methyl-2,3-bis(2-methoxyethoxy)-8H-quinazolino[4,3-b]quinazoline
- V-23 4-(3-(( 9-chloro-10-fluoro-3-methoxy-8H-quinazolino[4,3-b]quinazolin-2-yl)oxy)propyl)morpholine II
- V-23' 4-(3-((9-chloro-10-fluoro-3-methoxy-8H-quinazolino[4,3-b]quinazolin-2-yl)oxy)propane Morpholine
- V-24 9-chloro-3-methoxy-2-P-(tetrahydropyrrolyl-1-yl)propoxy)-8H-quinazoline[4,3-b] Quinazoline
- V-26 4-(3-((9-ethynyl-3-methoxy-8H-quinazolino[4,3-b]quinazolin-2-yl)oxy)propyl) Morpholine
- V-28 4-(3-((11-chloro-3-methoxy-8H-quinazolin[4,3-b]quinazolin-2-yl)oxy)propyl)morpholine, V-29 methanesulfonic acid- ⁇ 3-((9-nitro-8H-quinazolin[4,3-b]quinazolin-2-yl)oxy)propyl)morpholine-11-methanol ⁇
- Method 1 The compounds of the present invention can be synthesized by the following methods: Method 1:
- the method comprises dissolving a compound of the formula (I) and a compound of the formula (II) in a solvent A, and adding a base A or an acid B to obtain a compound of the formula (m), wherein the compound of the formula (m) is in a solvent B and trichloro
- the phosphine or methanesulfonyl chloride is reacted to obtain a fused ring quinazoline derivative represented by the formula (V), and the specific steps are as follows:
- the compound V was dissolved in 3 mol/L of acid/ethanol and cooled to precipitate a salt of the compound V.
- the acid was hydrochloric acid, hydrobromic acid, sulfuric acid, acetic acid, lactic acid, tartaric acid, citric acid, citric acid, and the like. Fluoroacetic acid, malic acid, maleic acid, succinic acid, p-toluenesulfonic acid or methanesulfonic acid, the salts are hydrochloride, hydrobromide, sulfate, acetate, lactate, tartrate, hydrazine Acid salt, citrate, trifluoroacetate, malate, maleate, succinate, p-toluenesulfonate
- the solvent A is: acetonitrile, isopropanol, dichloromethane, hydrazine, hydrazine-dimethylformamide or N,N-dimethylacetamide, 1, 4-dioxane
- solvent B is: Acetonitrile, chloroform, chloroform, toluene or benzene
- base A is: triethylamine, pyridine, potassium carbonate, diisopropylethylamine
- acid B is: formic acid, acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid.
- R 2 is hydrogen, halo, amino, nitro, hydroxyamino, carboxy, alkoxycarbonyl group, alkyl with d_c 4, d- C 4, acylamino, (E) 4- (dimethylamino) -2- An enoylamino group, an alkoxy group, a decyl group, a ureido group, a trifluoromethyl group, a d-C 4 sulfonyl group, an arylsulfonyl group, a substituted phenyl group, a phenyl group, a heterocyclic ring or a substituted heterocyclic ring;
- R 3 is hydrogen, halogen, trifluoromethyl, cyano, C 2 -C 4 alkynyl, nitro, amino, hydroxy, hydroxymethyl, sulfonate, d-C 4 thiol, D—C 4 decyloxy, d—C 4 acylamino, benzoylamino, d—c 4 substituted amino, unsaturated fatty chain, 5-membered aliphatic ring, 6-membered aliphatic ring, Substituted phenyl, phenyl, substituted benzyloxy or heterocyclic;
- R4 is hydrogen, trifluoromethyl, fluorenyl or d-C 4 decyloxy
- R 5 is hydrogen, halogen, trifluoromethyl, cyano, C 2 -C 4 alkynyl, nitro, amino, hydroxy, hydroxymethyl, decyl sulfonate, d-C 4 fluorenyl, D—C 4 alkoxy group, d—C 4 acylamino group, benzoylamino group, d—C 4 substituted amino group, —Ct unsaturated fatty chain, 5-membered aliphatic ring, 6-membered fat Ring, substituted phenyl, phenyl, substituted benzyloxy or heterocyclic;
- R 2 , R 4 and R 5 are not hydrogen at the same time.
- R 2 in the same general method, R 2 is the reaction of two-pass method 265 described above; R6 is hydrogen, methyl, ethyl or isopropyl.
- Compound VI and Compound IX can be purchased commercially or synthesized by conventional methods.
- the compound of the present invention or a salt thereof has strong inhibitory effects on epidermal growth factor receptor tyrosine kinase and aurora kinase, and has strong differentiation and anti-proliferation against certain tumor cells.
- Activity, 295 can be used to treat cancer and diseases associated with differentiation and proliferation, especially for blood cancer and solid tumors.
- the invention further relates to a composition
- a composition comprising a therapeutically effective amount of said compound or a salt thereof and a pharmaceutically acceptable carrier, such as a perfume, a sweetener, a liquid or a solid filler or diluent, etc.
- a pharmaceutically acceptable carrier such as a perfume, a sweetener, a liquid or a solid filler or diluent, etc.
- the carrier material is prepared into a common pharmaceutical preparation such as a tablet, a capsule, a powder, a syrup, a liquid, a suspension or an injection by a method known in the art, and the preparation usually contains the active ingredient in an amount of 1-70% by weight. Preferably, the weight content is 5-50%.
- the compound of the present invention can be administered clinically to mammals (including humans) by oral or injection means, particularly preferably orally.
- the dosage is 0.0001 ⁇ 200mg/kg body weight per day.
- the optimal dose will depend on the individual, usually at the beginning of the dose, and then gradually increase the amount.
- the fused ring quinazoline derivatives of the present invention have strong inhibitory activity against protein tyrosine kinases (such as epidermal growth factor receptor or blood 305 platelet-derived growth factor receptor), and also for aurora kinase. It has strong inhibitory activity and thus has strong anti-malignant activity. It is preferably used for the treatment of cancer, leukemia and diseases related to differentiation and proliferation.
- protein tyrosine kinases such as epidermal growth factor receptor or blood 305 platelet-derived growth factor receptor
- aurora kinase protein tyrosine kinases
- It has strong inhibitory activity and thus has strong anti-malignant activity. It is preferably used for the treatment of cancer, leukemia and diseases related to differentiation and proliferation.
- the present invention 310 breaks through the framework of the existing pharmaceutical structure and is a novel fused ring quinazoline compound having a certain rigid structure.
- the compound of the present invention not only has strong antagonistic action against tyrosine kinase, but also has a good inhibitory activity against aurora kinase, and is a novel compound which acts as a double target.
- the compound of the present invention has strong antagonistic effect on proliferation of various tumor cell lines, and its anti-cancer activity and anti-tumor 315 spectrum are stronger than the positive control drug erlotinib.
- the compound of the present invention has low acute toxicity, low side effects, and good drug-forming properties.
- the compound and its medicinal preparation have a good therapeutic effect on diseases caused by abnormal gene expression, such as tumors, endocrine disorders, immune system diseases, genetic diseases and nervous system diseases.
- V-2 (5.07 g, ll mmol), methylbutynol (1.00 g, 10 mmol), palladium acetate (0.006 g, 0.025 mmol), cuprous iodide 370 (0.012 g, 0.05 mmol), triphenylphosphine (0.08 g, 0.3 mmol), dissolved in 10 ml of triethylamine, and refluxed for 7 h under nitrogen.
- V-5 (0.50 g, 1.17 mmol) and 0.10 g of a 10% palladium on carbon catalyst (Pd/C) were dissolved in 15 ml of methanol, and the mixture was warmed to reflux and then hydrogenated under normal pressure for 5 h. Filtration, the filtrate was taken, and frozen in a refrigerator for about 7 hours to precipitate a large amount of solid, which was filtered and dried to give a white solid V-6' 0.36 g, yield 77.70%.
- Pd/C 10% palladium on carbon catalyst
- V-6 (0.50 g, 1.17 mmol) was dissolved in 10 ml of chloroform, and 0.05 ml of acetyl chloride was added dropwise in an ice water bath. Then it was allowed to react to room temperature for 3 h and the reaction was completed. After adding 20 ml of water and extracting the mixture three times with dichloromethane, the organic phase was combined, washed three times with water, three times with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Filtration, the filtrate was taken, concentrated under reduced pressure, and the crude crystals were recrystallized to afford white solids, ⁇ / RTI> ⁇ / RTI> ⁇ / RTI> ⁇ RTIgt;
- V-6 (0.50 g, 1.17 mmol) was dissolved in 10 ml of chloroform, and 0.18 g of benzoyl chloride was added dropwise in an ice water bath. Then, the temperature was raised to room temperature for 3 hours, and the reaction was completed. After adding 20 ml of water and extracting the mixture three times with dichloromethane, the organic phase was combined, washed three times with water, three times with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Filtration, the filtrate was taken, concentrated under reduced pressure, and the crude crystals were recrystallized to afford white solid, V.
- V-28 4-(3-((l l-Chloro-3-methoxy-8H-quinazoline [4,3-b] quinazolin-2-yl)oxy)propyl)morpholine
- M-25 (1.20g, 3mmol) and phosphorus oxychloride (31 ⁇ ) were obtained according to the preparation method of the general method of the product.
- the white solid was -30 0.62 g, and the yield was 59.90%.
- Ethyl 3,4-bis(2-methoxyethoxy)benzoate (15.00 g, 0.05 mol) and 50 ml of glacial acetic acid were obtained. While stirring in an ice bath, slowly add 65-68% of nitric acid to 13 ml. It was then stirred at room temperature for 24 h. The reaction mixture was poured into 500 ml of ice water, and the mixture was extracted with EtOAc EtOAc. Filtration and concentration of the filtrate gave ethyl 2-nitro-4,5-di(2-methoxyethoxy)benzoic acid ethyl ester as a brown oil (14.10 g, 82.22%).
- the in vitro inhibitory activity of the epidermal growth factor receptor tyrosine kinase of the compound was determined by reference to the EGFR inhibitor screening reagent 895 box Cat# PV3193, Invitrogen.
- the test compound was separately prepared into a solution of 200 ⁇ M and 40 ⁇ M, and the inhibition of the compound at this concentration was examined.
- the compound erlotinib hydrochloride was used as a positive control. The results are as follows:
- the in vitro inhibitory activity assay of the aurora-inhibitor of the compound was carried out in accordance with the specification of the Aurora Kinase Inhibitor Screening Kit (Cat# PV3174, Invitrogen).
- the test compound was separately prepared into a solution of 200 ⁇ M and 20 ⁇ M to test the inhibition of the compound at this concentration.
- Compound VX-680 (chemical name: ⁇ -(4-((4-((5-methyl-1-H-pyrazol-3-yl)amino)-6-(4-methylpiperidinyl-) 1-yl)pyrimidin-2-yl)thio)phenyl)cyclopropanecarboxamide, Aurora kinase inhibitor) is a positive control.
- the results are as follows:
- V-2 90.00 53.45 90.69 68.62 95.91 59.74 92.73 72.25
- MDA-MB-435S human breast cancer cells Colo320 human rectal cancer cell line, PC-3 human prostate cancer, HepG2 human liver cancer cell line, IC: 50 were measured by CCK-8 kit.
- Erlotinib HCl as a positive control, the specific results are as follows
- V-2 15.31 61.15 32.31 33.96 0.42 9.83 0.67 0.11 4.78
- Acute toxicity test The method reported by Zhang Juntian's "Modern Pharmacological Experimental Method" was used for preliminary screening. The compounds of V-2, V-15, V-20, V-22 and V-33 were counted by Bliss method. The LD 5Q for secondary administration was 2.05 g/kg, 925 2.97 g/kg, 0.75 g/kg, 1.34 g/kg, and 2.84 g/kg, respectively.
- the active ingredient is mixed with sucrose and corn starch, moistened with water, stirred uniformly, dried, pulverized and sieved, added with calcium stearate, uniformly mixed, and compressed.
- Each tablet weighs 200 mg and has an active ingredient content of 10 mg.
- Active ingredient any compound of V I- V49 20mg
- Preparation method The active ingredient is dissolved in water for injection, uniformly mixed, filtered, and the obtained solution is placed in an ampoule under aseptic conditions, 10 mg per bottle, and the active ingredient content is 2 mg/bottle.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112012028964A BR112012028964A2 (pt) | 2010-05-21 | 2011-05-20 | quinazolinas policíclicas, método de preparação das mesmas e seus usos |
AU2011255169A AU2011255169A1 (en) | 2010-05-21 | 2011-05-20 | Fused quinazoline derivatives and uses thereof |
KR1020127033456A KR20130045275A (ko) | 2010-05-21 | 2011-05-20 | 일종의 접합고리 퀴나졸린류 파생물 및 그의 응용 |
CN2011800261684A CN102918044A (zh) | 2010-05-21 | 2011-05-20 | 一种稠环喹唑啉类衍生物及其应用 |
EP11782976.2A EP2592083A4 (en) | 2010-05-21 | 2011-05-20 | CONDENSED QUINAZOLINE DERIVATIVES AND USES THEREOF |
MX2012013527A MX2012013527A (es) | 2010-05-21 | 2011-05-20 | Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas. |
RU2012147319/04A RU2012147319A (ru) | 2010-05-21 | 2011-05-20 | Полициклические хиназолины, их получение и применение |
CA2799989A CA2799989A1 (en) | 2010-05-21 | 2011-05-20 | Polycyclic quinazolines, preparation thereof, and use thereof |
JP2013511520A JP2013526590A (ja) | 2010-05-21 | 2011-05-20 | 縮環キナゾリン誘導体及びその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010182895.7 | 2010-05-21 | ||
CN201010182895 | 2010-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011144059A1 true WO2011144059A1 (zh) | 2011-11-24 |
Family
ID=44972984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/074434 WO2011144059A1 (zh) | 2010-05-21 | 2011-05-20 | 一种稠环喹唑啉类衍生物及其应用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110288086A1 (zh) |
EP (1) | EP2592083A4 (zh) |
JP (1) | JP2013526590A (zh) |
KR (1) | KR20130045275A (zh) |
CN (1) | CN102918044A (zh) |
AU (1) | AU2011255169A1 (zh) |
BR (1) | BR112012028964A2 (zh) |
CA (1) | CA2799989A1 (zh) |
MX (1) | MX2012013527A (zh) |
RU (1) | RU2012147319A (zh) |
WO (1) | WO2011144059A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013159698A1 (zh) * | 2012-04-26 | 2013-10-31 | 深圳信立泰药业股份有限公司 | 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106518879B (zh) * | 2016-09-21 | 2018-12-07 | 西安交通大学 | 一类2,3-内酰胺环稠合喹唑啉-4(3h)-酮衍生物及其制备方法和应用 |
CN106928069B (zh) * | 2017-03-21 | 2019-03-19 | 上海玉函化工有限公司 | 一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法 |
CN108358798A (zh) * | 2018-02-12 | 2018-08-03 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成厄洛替尼中间体的方法 |
CN113603650B (zh) * | 2021-08-03 | 2023-03-10 | 杭州职业技术学院 | 一种埃罗替尼关键中间体的催化环合制备方法及其应用 |
TW202315625A (zh) * | 2021-08-13 | 2023-04-16 | 大陸商深圳信立泰藥業股份有限公司 | 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
WO1997049688A1 (en) | 1996-06-24 | 1997-12-31 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
WO2005067933A1 (en) | 2004-01-16 | 2005-07-28 | F. Hoffmann-La Roche Ag | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system |
WO2007083096A2 (en) | 2006-01-21 | 2007-07-26 | Astrazeneca Ab | N- (2, 3-difluorophenyl) -2- [4- ( {7-methoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazoli n-4-yl}amino) -lh-pyrazol-1-yl] acetamide and n- (2, 3 -d i fluoro phenyl) -2- [4- ( {7-ethoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazolin |
CN101613356A (zh) * | 2009-07-23 | 2009-12-30 | 东南大学 | 喹唑啉类四环衍生物及制备方法和在制药中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199900636T2 (xx) * | 1996-09-23 | 1999-10-21 | Rutgers, The State University Of New Jersey | Anti-t�m�r ajanlar� olarak ikameli/katk�l� heterosayk�llar. |
US7262297B2 (en) * | 2003-05-15 | 2007-08-28 | Hoffmann-La Roche Inc. | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
CN101457251A (zh) * | 2007-12-10 | 2009-06-17 | 浙江大学 | 一种增敏肿瘤细胞药剂的筛选方法及其应用 |
-
2011
- 2011-05-20 JP JP2013511520A patent/JP2013526590A/ja active Pending
- 2011-05-20 KR KR1020127033456A patent/KR20130045275A/ko not_active Application Discontinuation
- 2011-05-20 CN CN2011800261684A patent/CN102918044A/zh active Pending
- 2011-05-20 BR BR112012028964A patent/BR112012028964A2/pt not_active IP Right Cessation
- 2011-05-20 RU RU2012147319/04A patent/RU2012147319A/ru not_active Application Discontinuation
- 2011-05-20 WO PCT/CN2011/074434 patent/WO2011144059A1/zh active Application Filing
- 2011-05-20 US US13/112,354 patent/US20110288086A1/en not_active Abandoned
- 2011-05-20 CA CA2799989A patent/CA2799989A1/en not_active Abandoned
- 2011-05-20 AU AU2011255169A patent/AU2011255169A1/en not_active Abandoned
- 2011-05-20 EP EP11782976.2A patent/EP2592083A4/en not_active Withdrawn
- 2011-05-20 MX MX2012013527A patent/MX2012013527A/es not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
WO1997049688A1 (en) | 1996-06-24 | 1997-12-31 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
WO2005067933A1 (en) | 2004-01-16 | 2005-07-28 | F. Hoffmann-La Roche Ag | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system |
WO2007083096A2 (en) | 2006-01-21 | 2007-07-26 | Astrazeneca Ab | N- (2, 3-difluorophenyl) -2- [4- ( {7-methoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazoli n-4-yl}amino) -lh-pyrazol-1-yl] acetamide and n- (2, 3 -d i fluoro phenyl) -2- [4- ( {7-ethoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazolin |
CN101613356A (zh) * | 2009-07-23 | 2009-12-30 | 东南大学 | 喹唑啉类四环衍生物及制备方法和在制药中的应用 |
Non-Patent Citations (4)
Title |
---|
ALEXANDRE FRANCOIS-RENE ET AL.: "Novel series of 8H-quinazolino[4,3-b]quinazolin-8-ones via two Niementowski condensations.", TETRAHEDRON, vol. 59, no. 9, 2003, pages 1413 - 1419, XP004409940 * |
J. MED. CHEM., vol. 29, 1986, pages 1406 - 1412 |
See also references of EP2592083A4 * |
TETRAHEDRON LETTERS, 2004, pages 6517 - 6521 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013159698A1 (zh) * | 2012-04-26 | 2013-10-31 | 深圳信立泰药业股份有限公司 | 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20130045275A (ko) | 2013-05-03 |
EP2592083A1 (en) | 2013-05-15 |
JP2013526590A (ja) | 2013-06-24 |
CN102918044A (zh) | 2013-02-06 |
CA2799989A1 (en) | 2011-11-24 |
EP2592083A4 (en) | 2014-01-22 |
MX2012013527A (es) | 2013-04-08 |
US20110288086A1 (en) | 2011-11-24 |
AU2011255169A1 (en) | 2013-01-17 |
BR112012028964A2 (pt) | 2016-07-26 |
RU2012147319A (ru) | 2014-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2602071C2 (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
CA2759241C (en) | Novel anti-inflammatory agents | |
WO2019134705A1 (zh) | 一种免疫调节剂 | |
JP3088018B2 (ja) | キナゾリン誘導体 | |
WO2016184434A1 (zh) | 一种吡啶并氮杂环化合物及其制备方法和用途 | |
TW200843777A (en) | Inhibitors of the hedgehog pathway | |
WO2011144059A1 (zh) | 一种稠环喹唑啉类衍生物及其应用 | |
JP2018529633A (ja) | ジアリール大環状多形 | |
CA2922077A1 (en) | Quinoline-substituted compound | |
WO2016011979A1 (zh) | 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途 | |
US20200024280A1 (en) | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr | |
US11566024B2 (en) | Tartrate of selective CDK9 inhibitor and crystal form thereof | |
JP6797923B2 (ja) | Alkおよびsrpk阻害剤ならびに使用方法 | |
US20230331703A1 (en) | Egfr inhibitors | |
JP2023522195A (ja) | 炎症性疾患の治療のための置換ピリジン | |
WO2015144021A1 (zh) | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 | |
JP2019518776A (ja) | Egfr阻害剤としてのアニリンピリミジン化合物の結晶 | |
US11572359B2 (en) | PARP/PI3K double-target inhibit containing pyridopyrimidine structure | |
WO2023178928A1 (zh) | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 | |
CN115322158B (zh) | 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物 | |
WO2019196938A1 (zh) | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 | |
JP2020526593A (ja) | N−フェニル−2−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法 | |
JP7110335B2 (ja) | プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体 | |
JP2022537385A (ja) | 大環状キナーゼ阻害剤の多形 | |
WO2013159698A1 (zh) | 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180026168.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11782976 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2533/MUMNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2799989 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013511520 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/013527 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20127033456 Country of ref document: KR Kind code of ref document: A Ref document number: 2012147319 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011782976 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011255169 Country of ref document: AU Date of ref document: 20110520 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012028964 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012028964 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121113 |